AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AIM ImmunoTech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.16−0.01 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $2.79M
- P/E (TTM)
- –
- Dividend yield
- –
AIM ImmunoTech statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Market Cap | $4.97M | $164.85M |
| Enterprise Value | -$1.38M | $87.06M |
| PS Ratio | 52.26 | 3.60 |
| PB Ratio | 0.64 | 2.03 |
| P/TBV Ratio | 0.82 | 2.31 |
Enterprise value
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| EV / Sales | -14.50 | 2.43 |
Income (trailing twelve months)
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Revenue | $95.00K | $57.94M |
| Operating Income | -$11.14M | -$21.44M |
| Net Income | -$14.27M | -$22.46M |
| EBITDA | -$11.14M | -$16.91M |
Margins
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Operating Margin | -11724.2% | -44.5% |
| Profit Margin | -15021.1% | -39.2% |
| EBITDA Margin | -11724.2% | -31.3% |
Returns
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Return on Equity (ROE) | -2382.3% | -53.1% |
| Return on Assets (ROA) | -169.3% | -41.0% |
| Return on Capital Employed (ROCE) | -143.1% | -37.8% |
Growth
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -21.5% | 6.01% |
| Revenue Growth (3Y CAGR) | -14.5% | 2.25% |
| Revenue Growth (5Y CAGR) | -11.6% | 6.42% |
Balance sheet
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.96M | $62.42M |
| Total Debt | $3.62M | $120.13M |
| Net Cash (Debt) | $6.34M | $15.68M |
| Net Cash Per Share | $0.21 | $0.66 |
| Equity (Book Value) | $7.74M | $48.79M |
| Book Value Per Share | $0.25 | $1.36 |
| Tangible Book Value | $6.03M | $23.06M |
| Working Capital | $5.49M | $75.77M |
Financial position
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Current Ratio | 2.11 | 3.30 |
| Quick Ratio | 2.01 | 2.39 |
| Debt / Equity | 0.47 | 0.51 |
| Interest Coverage | -9.79 | -7.12 |
Cash flow (trailing twelve months)
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.37M | -$12.35M |
Efficiency
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
Dividends and yields
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Earnings Yield | -287.4% | -22.7% |
Shares
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Shares Outstanding | 30,442,100 | 58,179,650 |
| Shares Change (YoY) | 887.2% | 11.1% |
| Shares Change (QoQ) | 252.5% | 0.54% |
| Float | 26,659,300 | 49,173,100 |
| Shares Held by Insiders | 12.4% | 11.6% |
| Shares Held by Institutions | 3.77% | 59.4% |
Scores
| Measure | AIM ImmunoTech | Industry median |
|---|---|---|
| Altman Z-Score | -50.99 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from AIM ImmunoTech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.